VYNE Therapeutics Provides Update on VYN202 Program

Core Points - VYNE Therapeutics Inc. announced a clinical hold on its Phase 1b study of VYN202 for moderate-to-severe plaque psoriasis due to observed testicular toxicity in dogs from a non-clinical toxicology study [1][2] - The company has suspended all screening, enrollment, and patient dosing in the Phase 1b trial and aims to resolve the clinical hold with the FDA as soon as possible [2] - The clinical hold does not affect VYNE's ongoing Phase 2b trial of repibresib gel for nonsegmental vitiligo, with top-line results expected mid-year [3] - The CEO of VYNE expressed disappointment over the clinical hold but emphasized the priority of patient safety and the intention to work closely with the FDA [4] - VYNE is focused on developing differentiated therapies for chronic inflammatory and immune-mediated conditions, utilizing its proprietary BET inhibitors [4]